| Assay ID | Title | Year | Journal | Article |
|---|
| AID105658 | Inhibitory concentration of the drug resulting in inhibition of cell growth to 50% of controls in MOLT-4 (human leukemia) | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
| Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. |
| AID88542 | Growth inhibitory concentration against human cervical carcinoma (HeLa) cell line | 2004 | Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
| Synthesis, biological activity, and quantitative structure-activity relationship study of azanaphthalimide and arylnaphthalimide derivatives. |
| AID83599 | Growth inhibitory concentration against human colon adenocarcinoma cell line (HT-29) | 2004 | Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
| Synthesis, biological activity, and quantitative structure-activity relationship study of azanaphthalimide and arylnaphthalimide derivatives. |
| AID156168 | In vitro cytotoxicity against human prostate carcinoma (PC-3) cell line | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
| New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties. |
| AID156159 | Inhibition of human prostate cancer cell line PC-3 growth | 2002 | Bioorganic & medicinal chemistry letters, May-06, Volume: 12, Issue:9
| Induction of apoptosis by aryl-substituted diamines: role of aromatic group substituents and distance between nitrogens. |
| AID91918 | Inhibitory concentration required to reduce cell number to 50% of control cultures in JLc(Jurkat human leukemia) | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
| Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. |
| AID411971 | Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
| Molecular modelling studies, synthesis and biological activity of a series of novel bisnaphthalimides and their development as new DNA topoisomerase II inhibitors. |
| AID120199 | Median survival time of treated mice (T) compared to controls expressed as a percentage (%T/C) at the dose of 5.0 mg/kg (dose administered intraperitoneally on days 1, 5 and 9). | 1997 | Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
| Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. |
| AID150951 | Inhibitory concentration required to reduce cell number to 50% of control cultures in P388 (murine leukemia cell line) | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
| Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. |
| AID85759 | Inhibitory concentration of the drug resulting in inhibition of cell growth to 50% of controls in HT-29 (human colon) | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
| Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. |
| AID83616 | In vitro cytotoxicity against HT-29 (human colon adenocarcinoma) cell line. | 1997 | Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
| Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. |
| AID120198 | Median survival time of treated mice (T) compared to controls expressed as a percentage (%T/C) at the dose of 3.3 mg/kg (dose administered intraperitoneally on days 1, 5 and 9). | 1997 | Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
| Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. |
| AID88545 | In vitro cytotoxicity against human cervical carcinoma (HeLa) cell line | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
| New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties. |
| AID229538 | Ratio of IC50 values obtained from Jurkat lines, (JLa /JLc) | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
| Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. |
| AID614634 | Binding affinity to supercoiled pRYG DNA at 0.1 uM after 10 mins by by agarose gel electrophoresis | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
| Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. |
| AID117101 | Median survival time of Compound on C57B1/6 mice which was implanted intraperitoneally with M5076 murine sarcoma cells at the dose of 2.2 mg/kg (dose administered intraperitoneally on days 1, 5 and 9). | 1997 | Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
| Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. |
| AID117103 | Median survival time of Compound on C57B1/6 mice which was implanted intraperitoneally with M5076 murine sarcoma cells at the dose of 5.0 mg/kg (dose administered intraperitoneally on days 1, 5 and 9). | 1997 | Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
| Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. |
| AID156008 | In vitro concentration required to reduce cell number to 50% in human postrate carcinoma (PC-3) culture | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
| Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides. |
| AID214410 | Inhibitory concentration of the drug resulting in inhibition of cell growth to 50% of controls in U937 (human leukemia) | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
| Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. |
| AID101814 | Inhibition of human breast cancer cell line MDA-MB-231 growth | 2002 | Bioorganic & medicinal chemistry letters, May-06, Volume: 12, Issue:9
| Induction of apoptosis by aryl-substituted diamines: role of aromatic group substituents and distance between nitrogens. |
| AID614626 | Cytotoxicity against RAOSMC after 3 days by cell counting analysis | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
| Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. |
| AID117104 | Median survival time of Compound on C57B1/6 mice which was implanted intraperitoneally with M5076 murine sarcoma cells at the dose of 7.5 mg/kg (dose administered intraperitoneally on days 1, 5 and 9). | 1997 | Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
| Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. |
| AID87567 | In vitro concentration required to reduce cell number to 50% in human cervical carcinoma (HeLa) culture | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
| Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides. |
| AID83959 | Cytotoxic effect on human colon carcinoma HT-29 cell line | 2001 | Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
| Synthesis of antitumor dendritic imides. |
| AID325166 | Binding affinity to supercoiled pRYG DNA by DNA intercalating assay | 2008 | Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
| Antiproliferative effects on human tumor cells and rat aortic smooth muscular cells of 2,3-heteroarylmaleimides and heterofused imides. |
| AID614627 | Cytotoxicity against human NCI-H460 cells after 3 days by cell counting analysis | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
| Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. |
| AID614632 | Cell cycle arrest in human NCI-H460 cells assessed as accumulation at sub-G0/G1 phase at IC50 after 20 hrs using propidium Iodide staining by flow cytometry in presence of 10% fetal calf serum | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
| Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. |
| AID120200 | Median survival time of treated mice (T) compared to controls expressed as a percentage (%T/C) at the dose of 7.5 mg/kg (dose administered intraperitoneally on days 1, 5 and 9). | 1997 | Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
| Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. |
| AID614630 | Cell cycle arrest in human NCI-H460 cells assessed as accumulation at S phase at IC50 after 20 hrs using propidium Iodide staining by flow cytometry in presence of 10% fetal calf serum | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
| Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. |
| AID100105 | Inhibitory concentration required to reduce cell number to 50% of control cultures in LL(Lewis lung carcinoma cell line) | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
| Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. |
| AID223983 | Inhibition of lck catalytic domain expressed in baculovirus (Not determined) | 2001 | Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
| Synthesis of antitumor dendritic imides. |
| AID85753 | In vitro concentration required to reduce cell number to 50% in human colon carcinoma (HT-29) culture | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
| Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides. |
| AID83613 | In vitro cytotoxicity against human colon carcinoma (HT-29) cell line | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
| New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties. |
| AID614628 | Selectivity ratio of IC50 for rat SMC to IC50 for human NCI-H460 cells | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
| Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. |
| AID614631 | Cell cycle arrest in human NCI-H460 cells assessed as accumulation at G2/M phase at IC50 after 20 hrs using propidium Iodide staining by flow cytometry in presence of 10% fetal calf serum | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
| Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. |
| AID614633 | Inhibition of topoisomerase 2-mediated relaxation of supercoiled pRYG DNA at 0.1 uM after 10 mins using ethidium bromide staining by agarose gel electrophoresis | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
| Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. |
| AID156164 | Growth inhibitory concentration against human prostate carcinoma (PC-3) cell line | 2004 | Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
| Synthesis, biological activity, and quantitative structure-activity relationship study of azanaphthalimide and arylnaphthalimide derivatives. |
| AID614629 | Cell cycle arrest in human NCI-H460 cells assessed as accumulation at G0/G1 phase at IC50 after 20 hrs using propidium Iodide staining by flow cytometry in presence of 10% fetal calf serum | 2011 | Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
| Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. |
| AID229539 | Ratio of IC50 values obtained from Jurkat lines, (JLd /JLc) | 2001 | Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
| Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. |
| AID117102 | Median survival time of Compound on C57B1/6 mice which was implanted intraperitoneally with M5076 murine sarcoma cells at the dose of 3.3 mg/kg (dose administered intraperitoneally on days 1, 5 and 9). | 1997 | Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
| Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. |
| AID120197 | Median survival time of treated mice (T) compared to controls expressed as a percentage (%T/C) at the dose of 2.2 mg/kg (dose administered intraperitoneally on days 1, 5 and 9). | 1997 | Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
| Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |